EPO, erythropoietin, 2056

N. diseases: 646; N. variants: 11
Disease: Middle Cerebral Artery Occlusion ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0740391
Disease: Middle Cerebral Artery Occlusion
Middle Cerebral Artery Occlusion 		0.080 Biomarker disease BEFREE P-EPO ameliorated MCAO-induced neurological deficit and reduced behavioral disorder and the infarct area. 31813204 2020
CUI: C0740391
Disease: Middle Cerebral Artery Occlusion
Middle Cerebral Artery Occlusion 		0.080 Biomarker disease BEFREE We administered EPO or saline 0, 24 and 48 h after tMCAo/sham surgery. 31683519 2019
CUI: C0740391
Disease: Middle Cerebral Artery Occlusion
Middle Cerebral Artery Occlusion 		0.080 Biomarker disease BEFREE The number of Ki-67-, nestin-, or doublecortin-immunoreactive cells in bilateral subventricular zones was higher in EPO/EGFP/3T3-treated MCAO rats than it was in untreated MCAO control animals, indicating the enhancement of neurogenesis after EPO/EGFP/3T3 treatment. 30920178 2019
CUI: C0740391
Disease: Middle Cerebral Artery Occlusion
Middle Cerebral Artery Occlusion 		0.080 Biomarker disease BEFREE Western blot results showed that the content of EPO in brain tissue in MCAO group significantly increased compared with sham group. 31679265 2019
CUI: C0740391
Disease: Middle Cerebral Artery Occlusion
Middle Cerebral Artery Occlusion 		0.080 Biomarker disease BEFREE Experimental groups were as follows: saline (injected once with saline 7 d after MCAO); hUCBC (1.2 × 10<sup>7</sup> total nucleated cells, injected once via the tail vein 7 d after MCAO); EPO (500 IU/kg, injected intraperitoneally for five consecutive days from 7 d after MCAO); and combination of hUCBC and EPO (hUCBC+EPO). 31024439 2019
CUI: C0740391
Disease: Middle Cerebral Artery Occlusion
Middle Cerebral Artery Occlusion 		0.080 Biomarker disease BEFREE We administered EPO or saline 0, 24 and 48 h after tMCAo. 31211943 2019
CUI: C0740391
Disease: Middle Cerebral Artery Occlusion
Middle Cerebral Artery Occlusion 		0.080 Biomarker disease BEFREE EPO was applied before (30 min) and after (24 and 48 h) MCAo. 29315561 2018
CUI: C0740391
Disease: Middle Cerebral Artery Occlusion
Middle Cerebral Artery Occlusion 		0.080 Biomarker disease BEFREE A total of 30 adult male C57 BL/6 mice were treated with EPO (5000 IU/kg) or vehicle after transient middle cerebral artery occlusion (MCAO). 28413924 2017